Senti Biosciences, INC. 8-K Filing
Ticker: SNTI · Form: 8-K · Filed: Mar 27, 2026 · CIK: 0001854270
Sentiment: neutral
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2026-03-27 08:01:49
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SNTI The Nasdaq Capital Marke
Filing Documents
- snti-20260327.htm (8-K) — 27KB
- ex991sntiq425earningsrelea.htm (EX-99.1) — 75KB
- senti_logoxpra.jpg (GRAPHIC) — 3KB
- 0001628280-26-021578.txt ( ) — 232KB
- snti-20260327.xsd (EX-101.SCH) — 2KB
- snti-20260327_lab.xml (EX-101.LAB) — 22KB
- snti-20260327_pre.xml (EX-101.PRE) — 13KB
- snti-20260327_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 27, 2026 , Senti Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 27, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SENTI BIOSCIENCES, INC. Date: March 27, 2026 By: /s/ Timothy Lu Name: Timothy Lu, M.D., Ph.D. Title: Chief Executive Officer and President